Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Deutetrabenazine→

Deutetrabenazine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1392826-25-3
Molecular formula
C19H21D6NO3
Molecular weight
323.46 g/mol
Drug class
Vesicular monoamine transporter 2 (VMAT2) inhibitormonoamine-depleting agent
Mechanism of action
Reversibly inhibits VMAT2, reducing uptake of monoamines into synaptic vesicles and thereby decreasing vesicular storage and release of dopamine and other monoamines. The precise contribution of individual monoamines to clinical effects is not fully established.
Indications / reported uses
  • Treatment of chorea associated with Huntington disease
  • Treatment of tardive dyskinesia in adults; dose and monitoring depend on product-specific CYP2D6 and safety requirements

Sources: US DailyMed — AUSTEDO (deutetrabenazine) · FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Vesicular monoamine transporter 2 (VMAT2) inhibitor; monoamine-depleting agent

Mechanism of action

Reversibly inhibits VMAT2, reducing uptake of monoamines into synaptic vesicles and thereby decreasing vesicular storage and release of dopamine and other monoamines. The precise contribution of individual monoamines to clinical effects is not fully established.

General use cases

  • Treatment of chorea associated with Huntington disease
  • Treatment of tardive dyskinesia in adults; dose and monitoring depend on product-specific CYP2D6 and safety requirements

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Deutetrabenazine Environmental Risk Assessment (ERA) (the Deutetrabenazine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.